M
M. Hie
Researcher at Paris-Sorbonne University
Publications - 15
Citations - 71
M. Hie is an academic researcher from Paris-Sorbonne University. The author has contributed to research in topics: Systemic lupus erythematosus & Neurosarcoidosis. The author has an hindex of 4, co-authored 15 publications receiving 56 citations.
Papers
More filters
Efficacy of Biological-Targeted Treatments in Takayasu ArteritisCLINICAL PERSPECTIVE: Multicenter, Retrospective Study of 49 Patients
A. Mekinian,Cloé Comarmond,M. Resche-Rigon,Tristan Mirault,Jean Emmanuel Kahn,Marc Lambert,Jean Sibilia,Antoine Néel,Pascal Cohen,M. Hie,Sabine Berthier,Isabelle Marie,Christian Lavigne,Marie Anne Vandenhende,Géraldine Muller,Zahir Amoura,Hervé Devilliers,Sébastien Abad,Mohamed Hamidou,Loïc Guillevin,Robin Dhote,Bertrand Godeau,Emmanuel Messas,Patrice Cacoub,Olivier Fain,D. Saadoun +25 more
TL;DR: This nationwide study shows a high efficacy of biological-targeted treatments in refractory patients with Takayasu arteritis with an acceptable safety profile.
Journal ArticleDOI
Les atteintes neurologiques au cours de la sarcoïdose : diagnostic et traitement
F. Cohen Aubart,Damien Galanaud,Julien Haroche,Dimitri Psimaras,A. Mathian,M. Hie,D. Le-Thi Huong Boutin,Frédéric Charlotte,E. Maillart,Thierry Maisonobe,Zahir Amoura +10 more
TL;DR: Le diagnostic repose sur the mise en evidence de granulomes epithelioides et gigantocellulaires sans necrose caseeuse, dans un contexte de presentation clinique, biologique et une imagerie compatibles, et apres exclusion des diagnostics differentiels.
Journal ArticleDOI
Sarcoïdose cardiaque : avancées diagnostiques et thérapeutiques
F. Cohen Aubart,Hilario Nunes,Alexis Mathian,Julien Haroche,M. Hie,D. Le-Thi Huong Boutin,Philippe Cluzel,Michael Soussan,Xavier Waintraub,Pierre Fouret,Dominique Valeyre,Zahir Amoura +11 more
TL;DR: There is no reliable prospective large study to guide therapeutic strategy for cardiac sarcoidosis and immunosuppressive drugs have not been largely studied, but methotrexate could be helpful and TNF-α antagonists have been used with success.
Journal ArticleDOI
Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter.
Nabiha Sbeih,Alexis Mathian,Alexis Mathian,Marc Pineton de Chambrun,R. Lhote,Noël Zahr,Micheline Pha,Fleur Cohen-Aubart,J. Haroche,M. Hie,Sophie Jouffroy,Neila Benameur,Hervé Devilliers,Zahir Amoura +13 more
TL;DR: Additional data is sought on the time needed, the probability of and the clinical predictors for achieving stable LLDAS and remission state under belimumab and the absence of relapse after an improvement of the disease.
Proceedings ArticleDOI
FRI0302 Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: clinical features, prognosis and treatment in a french multicentric cohort
Priscille Couture,M. Hie,M. Pineton De Chambrun,Lionel Galicier,N. Costedoat-Chalumeau,Alban Deroux,Tarik Kanouni,M. Roumier,I. Melki,A. Mathian,Paul Coppo,Z. Amoura +11 more
TL;DR: The clinical phenotype of TMA in lupus is described, the prognosis is specified and factors allowing early classification and management of the different subtypes are identified to provide prompt and appropriate management of this life-threatening complication.